Hematological Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

FEATURES AND HIGHLIGHTS

  • Feature: Dismissing a Problem
 Patient in 10 Safe Steps

    Most clinicians have dealt with a dissatisfied or noncompliant patient. 
But how do you end the relationship without putting yourself at risk?
  • New Product: MARQIBO

    Indication(s): Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or has progressed following ≥2 anti-leukemia therapies.
  • New Product: ICLUSIG

    Indication(s): Chronic, accelerated, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy.

News

Nymalize May Reduce Fatal Errors in Brain Hemorrhage Patients

The FDA has approved a new oral formulation to help reduce fatal medication errors in improving outcome for patients with subarachnoid hemorrhage.

Biogen Idec's Hemophilia A and B Candidates Under Review

The FDA has accepted the Biologics License Application for Eloctate, a first in class recombinant factor VIII Fc fusion protein for hemophilia A treatment.

Low-Dose Warfarin Safe With Bileaflet Mechanical Valve

For patients requiring aortic valve replacement, lower-dose warfarin after implantation with an approved mechanical valve prosthesis is safe and effective, with a lower bleeding risk than with standard-dose anticoagulant therapy.

Lifestyle Changes May Reduce Blood Clot Risk

Simple lifestyle changes, including exercising and maintaining a healthy body mass index, may reduce the risk of blood clots.